A randomized, controlled trial comparing topical steroid application to wet versus dry skin in children with atopic dermatitis (AD) - 20/07/16
Abstract |
Background |
Soak and smear (SS), a technique whereby a bath is followed by topical corticosteroid (TCS) application to wet skin, is reported to be a beneficial adjunctive therapy for patients with recalcitrant atopic dermatitis (AD).
Objective |
We evaluated whether SS is of greater benefit than application of TCS to dry skin for the treatment of childhood AD.
Methods |
A randomized, investigator-blinded, controlled study was performed in children with AD. Patients were randomized to apply TCS either via SS (n = 22) or to dry skin (n = 23) for 14 days. The primary outcome was an improvement in the Eczema Area and Severity Index score. Secondary outcomes included assessments of disease burden, pruritus, and sleep; morning cortisol levels; and adverse effects.
Results |
Patients with AD severity who applied TCS via SS or to dry skin improved 84.8% (95% confidence interval 77.5-92.1) and 81.4% (95% confidence interval 70.3-92.4) by Eczema Area and Severity Index score, respectively. There was no statistical difference between the 2 groups (P value = .85).
Limitations |
Small sample size limited the power of our study.
Conclusions |
We did not find that application of TCS to presoaked skin works better than application to dry skin for the treatment of AD in children.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, bath, corticosteroids, eczema, hydration, soak and smear
Abbreviations used : AD, EASI, SS, TCS
Plan
| Supported by Yale University School of Medicine James G. Hirsch, MD, Endowed Medical Student Research Fellowship. |
|
| Dr Antaya has been a consultant for the following: Promius, Anacor, Astellas, Ranbaxy, Pierre Fabre, and Hoffman-Laroche Pharmaceuticals. Drs Kohn and Kang have no conflicts of interest to declare. |
Vol 75 - N° 2
P. 306-311 - août 2016 Retour au numéro
Article précédent
- OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
- Jon M. Hanifin, Charles N. Ellis, Ilona J. Frieden, Regina Fölster-Holst, Linda F. Stein Gold, Angelo Secci, Angela J. Smith, Cathy Zhao, Elena Kornyeyeva, Lawrence F. Eichenfield
- Inflamed skin predisposes to sensitization to less potent allergens
- Nita Kohli, Susan Nedorost
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?